



NAME and FAMILY NAME	Giovambattista Capasso
DATE OF BIRTH	6th March 1950
HIGHEST DEGREE (e.g. full professor, clinical or post-graduate professor, doctor)	Full Professor of Nephrology
HONORS (e.g. FERA, FASN, FAKF, etc.)	FERA
PRESENT POSITION or ACADEMIC AFFILIATION	Director Department of Translational Medical Sciences University of Campania "Luigi Vanvitelli", Naples ITALY
PRESENT EDITORIAL POSITIONS in International and National Journals (up to seven)	Blood Purification (Associate Editor) Journal of Nephrology (Associate Editor) Nephrology Dialysis Transplantation (Associated Editor) Journal of Onco-Nephrology (Associated Editor) Kidney and Blood Pressure Research (Editor in Chief)
AREA OF EXPERTISE (basic, clinical, both) Please also indicate the specific area of interest (e.g. CKD progression, kidney failure, Hypertension, GNitis and Immunopathology, etc.)	Basic, Clinical - Acid-base and electrolytes regulation, hormonal control; - Functional genomics - Translational nephrology, particularly in the field of hypertension and tubulopathies - Onconeurology
NUMBER OF PUBMED PUBLICATIONS	249 (first one dated 1975)
5 MOST QUOTED PUBLICATIONS Kindly specify the number of quotations of each publication	<ol style="list-style-type: none">1. Pfeffer MA, Burdmann EA, Chen CY, et al. for TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Quotation 16602. Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010 Aug 25;2(46):46ps42. doi: 10.1126/scitranslmed.3001249. Quotation 2303. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRIZE Trial Investigators. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030 Quotation 808

	<ol style="list-style-type: none"> 4. Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. <i>Nephrol Dial Transplant</i>. 2016 Mar;31(3):337-48. doi: 10.1093/ndt/gfv456. Quotation 104 5. EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. <i>N Engl J Med</i>. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Quotation 614
HIRSCH-INDEX (calculated by Google Scholar)	40
INTERNATIONAL AWARDS (up to three)	<ol style="list-style-type: none"> 1. 1983 - 1984 International Fellowship Award da parte del Fogarthy International Center, National Institute of Health, Bethesda (USA). 2. Maggio 1983 Award da parte della New York Society of Nephrology, New York (USA). 3. Febbraio 1989 Award da parte del Council for International Exchange of Scholars, Fulbright Commission, USA.

Data updated as March 2019